Skip to content

The Relations Among Endotoxin, Inflammatory Cytokines, Cognitive Markers and Brain MRI Changes in Subjects With Depressive Disorder

The Relations Among Endotoxin, Inflammatory Cytokines, Cognitive Markers and Brain MRI Changes in Subjects With Depressive Disorder

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06203015
Enrollment
150
Registered
2024-01-12
Start date
2022-06-01
Completion date
2024-06-01
Last updated
2024-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder, Inflammation, Cognitive Dysfunction, Endotoxemia, Genetic Predisposition to Disease, Blood Brain Barrier Defect

Keywords

Major depressive disorder, Inflammation, Endotoxin, Cognitive dysfunction, Genetic polymorphisms, Multiparametric Magnetic Resonance Imaging, Blood Brain Barrier

Brief summary

Major depressive disorder (MDD) is a chronic mental illness, with 60% lifetime risk of recurrence after the first MDD episode. Despite available treatment options for MDD, only about half to two-thirds of patients respond to first-line antidepressant treatment, and only 30% to 45% of patients achieve remission. Scholars assume that this low remission rate and high rate of treatment resistance are due to the polyetiological nature of the disease, the heterogeneity of the clinical picture of depression, and the lack of biomarkers to stratify MDD subtypes. The aetiology of MDD, although researched extensively, remains unclear. None of the known mechanisms alone explains the pathogenesis of depression, meaning that the interplay of several factors contributes to the development of MDD. Accumulated scientific evidence has supported the importance of the immune system in the etiopathogenesis of MDD. Until now, the cause of the low-grade inflammation observed in this subgroup of MDD patients has been unclear. In the proposed study, the investigators will test a new hypothesis of the immune theory of the development of MDD: the endotoxin hypothesis of neurodegeneration. This hypothesis states that endotoxin, causes or contributes to neurodegeneration. Blood plasma levels of LPS are normally low but are elevated during infections, gut inflammation, gum disease, and neurodegenerative diseases. Dysbiosis may promote increased intestinal permeability (leaky gut), which leads to bacterial translocation across the intestinal barrier and into the circulation, thus forming of LPS and LPS-binding protein complex, which triggers the secretion of cytokines. Data suggest that LPS-induced peripheral inflammation can activate neuroinflammation. However, it is not known whether a low-level persistent presence of LPS in the circulatory system can cause low-grade chronic neuroinflammation leading to neurodegeneration and/or symptoms of MDD. Based on existing preclinical and clinical research data, the investigators hypothesise that an increase in blood plasma endotoxin and peripheral cytokines induce BBB dysfunction, neuroinflammation and neurodegenerative processes in specific etiologically relevant structures of the brain and cause clinical manifestation of depressive symptoms and cognitive damage. In this study the investigators are also going to investigate the effects of single nucleotide polymorphisms of four genes in relation to blood plasma endotoxin and peripheral cytokines concentrations and clinical manifestation of MDD.

Interventions

DIAGNOSTIC_TESTThe Cambridge Neuropsychological Test Automated Battery.

to determine cognitive dysfunction

DIAGNOSTIC_TESTVenous blood samples

to measure levels of cytokines, endotoxin, and genetic markers.

DIAGNOSTIC_TESTbrain MRI

to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations

DIAGNOSTIC_TESTthe Montgomery-Åsberg Depression Rating Scale

to measure severity of depressive symptoms

OTHERquestionnaire prepared by the researchers

collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.

Sponsors

Lithuanian University of Health Sciences
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* ≥18 years old * signed informed consent * patients diagnosed with MDD (according to the WHO's \[2019\] International Classification of Diseases and related health problems categorization of mental disorders) for MDD group.

Exclusion criteria

* diagnosis of other mental disorders during the past one-year period (for MDD group). * diagnosis of any mental disorders within the past one-year period, previous suicide attempt, or current suicide risk identified in the study (for control group). * diagnosis of somatic diseases that may affect changes in inflammatory factors in the body (for both groups)

Design outcomes

Primary

MeasureTime frameDescription
Levels of blood plasma endotoxin and inflammatory cytokines between groups.Day 1To evaluate the concentrations of blood plasma endotoxin and inflammatory cytokines among patients with MDD and in a control group. We hypothesize that an increase in blood plasma endotoxin is associated with an increase in blood inflammatory cytokines in the group of patients with MDD.
Severity and manifestation of depressive symptoms.Day 1Evaluate the severity and manifestation of different depressive symptoms. We hypothesize that endotoxin and inflammatory markers are associated with specific symptoms of MDD, allowing us to identify MDD patients with a specific LPS-induced/stimulated inflammatory depression subtype.

Secondary

MeasureTime frameDescription
Brain MRIDay 1Perform a multiparametric brain MRI assessment of depressed patients and a control group. We hypothesize that, among patients with MDD, there are changes in blood-brain barrier permeability to water, levels of neuroinflammation and perfusion, and structural neurodegenerative changes that are associated with blood plasma endotoxin and cytokine concentrations.
Cognitive dysfunctionDay 1Evaluate cognitive functions. We hypothesize that low-grade neuroinflammation negatively affects cognitive performance among patients with MDD.
CovariatesDay 1Perform a subgroup analysis on neuroinflammation markers based on individuals' BMI and smoking status.
Genetic markersDay 1Determine possible genetic markers among MDD subjects in relation to blood plasma endotoxin and inflammatory cytokines concentrations that could predict a genetic predisposition to neuroinflammation, neurodegeneration and the development of MDD.

Countries

Lithuania

Contacts

Primary ContactEgle Milasauskiene, MD
egle.milasauskiene@lsmu.lt+37063458861

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026